These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 38187388)

  • 1. The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer.
    Ding K; Mou P; Wang Z; Liu S; Liu J; Lu H; Yu G
    Front Immunol; 2023; 14():1298524. PubMed ID: 38187388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
    Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
    Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
    Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
    Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
    Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of immune checkpoint inhibitors in colorectal cancer.
    Wang L; Huang C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
    Wang Q; Shen X; Chen G; Du J
    Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative immune checkpoint inhibition for colorectal cancer: recent advances and future directions.
    Chen JT; Zhou YW; Han TR; Wei JL; Qiu M
    Front Immunol; 2023; 14():1269341. PubMed ID: 38022667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target.
    Wang H; Zhou Y; Zhang Y; Fang S; Zhang M; Li H; Xu F; Liu L; Liu J; Zhao Q; Wang F
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer.
    El Hajj J; Reddy S; Verma N; Huang EH; Kazmi SM
    J Gastrointest Cancer; 2023 Dec; 54(4):1017-1030. PubMed ID: 37009977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
    Almquist DR; Ahn DH; Bekaii-Saab TS
    BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective.
    Liu N; Shan F; Ma M
    Int Immunopharmacol; 2021 Oct; 99():108017. PubMed ID: 34352568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.
    Cohen R; Rousseau B; Vidal J; Colle R; Diaz LA; André T
    Target Oncol; 2020 Feb; 15(1):11-24. PubMed ID: 31786718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognosis and immunotherapy efficacy in dMMR&MSS colorectal cancer patients and an MSI status predicting model.
    Fu X; Huang J; Zhu J; Fan X; Wang C; Deng W; Tan X; Chen Z; Cai Y; Lin H; Wang G; Zhang N; Zhu Y; Chen J; Zhan H; Huang S; Fang Y; Li Y; Huang Y
    Int J Cancer; 2024 Aug; 155(4):766-775. PubMed ID: 38594805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability in mismatch repair proficient colorectal cancer: clinical features and underlying molecular mechanisms.
    Xu Y; Liu K; Li C; Li M; Zhou X; Sun M; Zhang L; Wang S; Liu F; Xu Y
    EBioMedicine; 2024 May; 103():105142. PubMed ID: 38691939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Next-Generation Sequencing for the Detection of Microsatellite Instability in Colorectal Cancer With Deficient DNA Mismatch Repair.
    Ratovomanana T; Cohen R; Svrcek M; Renaud F; Cervera P; Siret A; Letourneur Q; Buhard O; Bourgoin P; Guillerm E; Dorard C; Nicolle R; Ayadi M; Touat M; Bielle F; Sanson M; Le Rouzic P; Buisine MP; Piessen G; Collura A; Fléjou JF; de Reyniès A; Coulet F; Ghiringhelli F; André T; Jonchère V; Duval A
    Gastroenterology; 2021 Sep; 161(3):814-826.e7. PubMed ID: 33992635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunocheckpoint Inhibitors in Microsatellite-Stable or Proficient Mismatch Repair Metastatic Colorectal Cancer: Are We Entering a New Era?
    Matteucci L; Bittoni A; Gallo G; Ridolfi L; Passardi A
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
    Quiroga D; Lyerly HK; Morse MA
    Curr Treat Options Oncol; 2016 Aug; 17(8):41. PubMed ID: 27315067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitochondrial DNA copy number plays opposing roles in T-lymphocyte infiltration of colorectal cancer based on mismatch repair status: new directions for immunotherapy?
    Chen M; Liu H; Liang W; Huang P; Ye F; Cai Y; Liang Z; Xiong L; Kang L; Huang L
    Br J Cancer; 2024 Mar; 130(5):798-807. PubMed ID: 38218920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
    Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
    Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.